CADTH | pCODR PAN-CANADIAN ONCOLOGY DRUG REVIEW

PROVINCIAL FUNDING SUMMARY

Romidepsin (Istodax) for Peripheral T-Cell Lymphoma (pCODR 10048)

pERC Recommendation: Recommends with conditions

For further details, please see pERC Final Recommendation

Notification to Implement Issued by pCODR: June 3, 2015

This information is current as of October 1, 2020.

Note: Funding criteria as listed on the decision date. Please refer to the provincial drug programs for the most recent funding criteria and program eligibility.

PROVINCE	STATUS	DECISION DATE	FUNDING CRITERIA
BC	Funded	Feb 1, 2017	Patients with symptomatic relapsed/refractory PTCL with at least one prior treatment. Use with caution in patients with history of cardiac dysfunction. A Compassionate Access Program (CAP) approval is required prior to the initiation of treatment (please refer to https://cap.phsa.ca/).
AB	Funded	Dec 18, 2015	Criteria Updated: For patients with relapsed/refractory peripheral T-cell lymphoma (PTCL) who are not eligible for transplant, have received at least one prior systemic therapy and have an ECOG performance status of 0 to 2. Physicians may choose either romidepsin or praletrexate in an individual patient but not both (unless due to intolerance, cannot sequence due to progression).
SK	Funded	Oct 1, 2015	Patients with relapsed or refractory peripheral T-cell lymphoma who have been previously treated, are ECOG 0 to 2 and are not eligible for transplant.
MB	Funded	Jan 1, 2016	For the treatment of patients: - with relapsed/refractory peripheral T-cell lymphoma AND - who are ineligible for stem cell transplantation* AND - who have undergone previous systemic therapy AND - who have an Eastern Cooperative Oncology Group performance status of 2 or less * Patients who have undergone previous stem cell transplant are eligible for treatment.
ON	Funded	Jan 11, 2016	Patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) who are ineligible for transplant and who have undergone previous systemic therapy; and have an Eastern Cooperative Performance Status (ECOG) of 0 to 2. Patients will be eligible for either pralatrexate or

PROVINCE	STATUS	DECISION DATE	FUNDING CRITERIA
			romidepsin, but not both. Dosing Regimen: 14 mg/m2 intravenously on days 1, 8 and 15 (cycle length is 28 days), until disease progression or unacceptable toxicity.
NS	Funded	Feb 1, 2016	As a single agent for patients with relapsed/refractory peripheral T-cell lymphoma (PTCL) who are ineligible for transplant and who have undergone previous systemic therapy and have an ECOG performance status (PS) of 0-2.
NB	Funded	July 21, 2016	For patients with relapsed/refractory peripheral T-cell lymphoma (PTCL) who are not eligible for transplant*, have received at least one prior systemic therapy and, have an ECOG performance status of 0 to 2. * patients who have previously undergone transplant are eligible for treatment
NL	Under Provincial Consideration		
PEI	Funded	Feb 1, 2019	Peripheral T-cell lymphoma (PTCL) -Patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) who are ineligible for transplant and who have undergone previous systemic therapy. -Eastern Cooperative Performance Status (ECOG) of 0 to 2 -Dosing: Romidepsin 14 mg/m2 intravenously on days 1, 8 and 15 (cycle length is 28 days). -Treatment will continue until progression or unacceptable toxicity.

Under provincial consideration means that the province is reviewing pCODR's recommendation. This may include the province working with the drug manufacturer to reach an agreement for a drug product that both parties can accept, in particular in cases where the pCODR Expert Review Committee has recommended that the drug be funded only on the condition of cost-effectiveness being improved to an acceptable level. This may occur before or after the pan-Canadian Pharmaceutical Alliance negotiations. Please contact the specific provincial drug program and/or cancer agency in your province for information about the status of a given drug product.